- Report
- January 2024
- 80 Pages
Argentina
From €2465EUR$2,595USD£2,100GBP
- Report
- April 2024
- 132 Pages
Global
From €903EUR$950USD£769GBP
- Report
- November 2021
- 365 Pages
Global
From €3325EUR$3,500USD£2,833GBP
- Report
- November 2021
- 233 Pages
Global
From €2375EUR$2,500USD£2,023GBP
- Book
- September 2023
- 272 Pages
Preimplantation Genetic Diagnosis (PGD) is a biotechnology procedure used to detect genetic abnormalities in embryos prior to implantation. It is used in conjunction with in vitro fertilization (IVF) to help couples with a family history of genetic disorders or those at risk of transmitting a genetic disorder to their offspring. PGD involves the removal of a single cell from an embryo and testing it for genetic abnormalities. The results of the test are then used to determine which embryos are suitable for implantation.
PGD has been used to detect a wide range of genetic disorders, including cystic fibrosis, Down syndrome, and Huntington's disease. It has also been used to detect chromosomal abnormalities, such as aneuploidy, which can lead to miscarriage or birth defects. PGD has been used to select embryos for gender selection, as well as to select embryos for tissue typing for bone marrow transplantation.
Companies in the Preimplantation Genetic Diagnosis market include Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Agilent Technologies, Inc., and Natera, Inc. Show Less Read more